Baird analyst David Rescott lowered the firm’s price target on Merit Medical (MMSI) to $110 from $111 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results which showed the tariff hit wil weigh on 2025 earnings but its CGI drivers keep 2026 unchanged.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MMSI:
- Merit Medical price target lowered to $106 from $117 at Wells Fargo
- Merit Medical price target lowered to $106 from $112 at Piper Sandler
- Merit Medical Systems: Strong Performance and Growth Potential Amid Tariff Challenges
- Merit Medical Systems: Strong Q1 Performance and Strategic Positioning Justify Buy Rating Despite Tariff Challenges
- Merit Medical price target lowered to $108 from $127 at Canaccord